Well Dr. Demopulos would have served his shareholders better over the last four years if he hadn't been continually promising a partnership "real soon now" on some of the GPCR projects.
This MASP-2 project has always been the most interesting by far of the projects that the company has discussed. It's not just a drug - they own a lot of the IP surrounding the pathway.
Market Data 
Markets 
AI
